高脂血症是动脉粥样硬化性心血管疾病的核心危险因素,随着生活水平提高并伴随饮食结构变化,其患病率呈持续上升趋势。现有降脂药物虽治疗成效显著,但长期应用存在潜在副作用,中药活性成分黄连素在血脂调节中展现出良好潜力,成为降脂药物领域的研究新热点。本文系统性回顾黄连素治疗高脂血症的最新研究进展,综合评估其单用或与他汀类药物联用的临床疗效与安全性证据,分析其改善血脂谱的有效性与耐受性,总结研究成果与现存挑战,为黄连素作为降脂药物的后续深入研究提供参考。

Hyperlipidemia is a central risk factor for atherosclerotic cardiovascular disease, and its prevalence has continued to increase alongside improved living standards and shifts in dietary patterns. Although currently available lipid-lowering agents deliver substantial clinical benefits, long-term therapy may be accompanied by potential adverse effects, underscoring the need for complementary options with favorable safety profiles. Berberine, a bioactive constituent derived from traditional Chinese medicine, has shown promising lipid-regulatory activity and has emerged as a growing focus in the development of novel lipid-lowering therapies. This paper systematically summarizes recent advances in berberine for hyperlipidemia and critically appraises clinical evidence regarding its efficacy and safety as monotherapy or in combination with statins. In addition, it evaluates its effectiveness and tolerability in improving lipid profiles, highlights key findings and remaining challenges, and provides a basis for future evidence-based research and therapeutic development of berberine as a lipid-lowering agent.

洛阳市科学技术协会河洛青年人才托举工程（2025HLTJ44）：青蒿琥酯靶向PARP1调控PI3K/AKT和SIRT1/PPARα轴改善HepG2细胞糖脂代谢的研究